Pharma Innovation 2019

October 25, 2019

Discover the latest tech and systems that have changed the game in pharmaceutical manufacturing

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

OTHER WHITEPAPERS
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

A Vision for the Global Generic and Biosimilar Medicines Industry

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

Read More
news image

The Ultimate Guide to Pharmaceutical Quality Managemen

whitePaper | October 20, 2022

When the first Nokia and Motorola cell phones that were affordable and small enough to fit in your pocket hit the market, they not only changed how we viewed phone technology but how we communicated.

Read More
news image

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More
news image

Pharma R&D Annual Review 2023

whitePaper | April 20, 2023

Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Read More

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

Events